Please assess the completion status of the following clinical trial:

Trial Title: MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of relapsing-remitting multiple sclerosis (RRMS)~* ability to consent and a written approval~* First acute ON attack to the fit eye within 30 days before screening~* Age 18 - 55 years at screening~* EDSS ≤ 6.0~* No MS Attack except for ON in the last 30 days before screening~* No immunomodulatory therapy for at least three Months (before randomization), or~* strong immunomodulatory therapy with interferon beta or glatiramer acetate for at least 6 months~* visus in the affected eye at least 0.1~* latency of Conventional VEP in the affected eye~  * = 115 ms or difference\> = 15 ms to the opposite side at a Study at least 4 but no more than 6 weeks after Onset of clinical symptoms~* At least 2 T2 lesions typical of MS in a previous MRI~Exclusion Criteria:~* other MS course than RRMS~* any condition which could interfere or prevent the MRI study or other investigations~* known allergy or intolerance, or other contraindication against Gd-DTPA~* Patients with known contraindications to treatment with fingolimod (Gilenya ®) or interferon beta-1b Extavia ®~* Competing diseases which could affect visual functions such as diabetic, retinopathy, glaucoma, retinal detachment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Fingolimod (Gilenya®) (Type: EXPERIMENTAL): 0,5 mg once a day in the morning, oral
- Interferon beta-1b (Extavia®) (Type: ACTIVE_COMPARATOR): every second day, s.c.

Based on this trial design, predict the completion outcome and termination type (if applicable).